durvalumab,paclitaxel,carboplatin,cisplatin,gemcitabine,pemetrexed
astrazeneca
['nsclc', 'aegean', 'sclc']
 giving a tour de force discussion of aegean neoadjuvant-adjuvant trial in early stage nsclc at aacr23. concludes that this regimen is a new soc but not yet the soc, given other positive trials in this space. awaiting ctdna for mrd 
Medical Oncologist & clinical-translational researcher in lung cancer. Co-Director-Center for Experimental Therapeutics, UC Davis Comprehensive Cancer Center